Could Regeneron Be The Best Biotech Stock To Buy?

Published: Aug 18, 2017

It may not get the attention as often as larger-cap biotech stocks like Celgene Corp. and Gilead Sciences, but a bunch of recent drug approvals could soon change that for Regeneron Pharmaceuticals. Is Regeneron Pharmaceuticals about to reward investors with a steady stream of big-time sales and profit growth?

In this episode of the Motley Fool's Industry Focus: Healthcare podcast, host Kristine Harjes is joined by Todd Campbell to explain why it could be an exciting time to become a Regeneron Pharmaceuticals shareholder.

Back to news